Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

1 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2008-005304-93-GB (EUCTR)	13/02/2009	12/12/2008	A Randomised Control Trial To Evaluate Whether Zoledronate Prevents Bone Loss In Acute Exacerbations Of Multiple Sclerosis - Zoledronate in multiple sclerosis	A Randomised Control Trial To Evaluate Whether Zoledronate Prevents Bone Loss In Acute Exacerbations Of Multiple Sclerosis - Zoledronate in multiple sclerosis	Bone loss in patients with Multiple Sclerosis (MS) who require large short term doses of methylprednisolone for exacerbations of their disease. MedDRA version: 9.1;Level: LLT;Classification code 10048393;Term: Multiple sclerosis relapse MedDRA version: 9.1;Classification code 10065687;Term: Bone loss	Trade Name: Aclasta 5mg solution for infusion Product Name: Aclasta Product Code: ZOL446H	North Bristol Trust	NULL	Not Recruiting			Female: yes Male: yes			United Kingdom